Elite Pharmaceuticals Inc (QB) (ELTP)

Shortages:


FDA shortage link for Adderall
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1

FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c

FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c

FDA shortage link for Naltrexone ( NOT IN SHORTAGE )
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c

ELTP

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass in vivo. Eliquis may have been the most sure thing of the 3 at that point but Nasrat even admitted last year that they weren’t settled on a filing strategy yet. Valuations get periodically updated as events develop.

Thx for correction - completely misread. Will be interesting to see which drug this turns out to be. Lots of guesses as to what it was and we don’t know the count of generic mfrs already in market. 

Ever heard of boilerplate language?

It seems the topic of transfer to another company was brought up during the argument. M&A’s do not happen every day. This is the potential first sign we have a buyer.
1. Elite was put up for sale 11 months ago, and The Rat wanted a sale done or near done by 31 Dec 2025.....as evidenced on the conference call. There was NO Eliquis filing, NO OxyContin settlement, and NO positive ANDA BE study even at the 31 Dec 2025 deadline, so your statement completely falls on its face. Even during the Feb 2026 conference call NONE of these three things had happened, and ALL "opportunities" were already presented to Elite to sell the company.

2. NONE of the news recently will affect the buyout price......AT ALL. If you don't think Jefferies ALREADY had all this in their financial models then I got a bridge to sell you. The valuation was completed LAST SUMMER.

These andas are here to increase the sale price of the company.
The Rat: "We may use part of the $12 million loan to purchase Mikah's stake of the Adderalls."

The Rat: "The Board proposed an Agreement to purchase the Adderalls from Mikah, which was ACCEPTABLE."

The Rat: "We are concluding all the partnerships that we have whenever we have the opportunity to do so. And we wanna convert EVERYTHING to Elite-owned and Elite-operated.”

Think. Elite pay Nasrat for Mikah?

They would have said conflict of interest. Nasrat on both sides of the transaction.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680716

One thing is 100% sure: at the time Nasrat picked that one its iqvia market value was higher than $1billion. Because it was a needle mover. !!!

He delivers to his promises.

- "IQVIA reported branded *AND* generic product sales for the twelve months ending April 2026 of $840 million."

Just seeing this now. It’s $840M in generic, NOT branded. That’s an awesome potential market right there.
2015 10-K - June 15 - Accelerated Filer
2016 10-K - June 15 - Accelerated Filer
2017 10-K - June 14 - Accelerated Filer
2018 10-K - June 14 - Accelerated Filer
2019 10-K - June 21 - Accelerated Filer (1 week delay - Notification of inability to timely file 10-K)
2020 10-K - June 30 - Covid Waiver?
2021 10-K - June 14 - Accelerated Filer

Elite always reports when they are required, not earlier, not later. They have never been required to report mid-June. It’s always 90-days after year end.

As of TODAY:

Elite Laboratories, Inc. (Reverified 06/15/2026)

Vyvanse - Limited Availability

Elite Laboratories, Inc. (Reverified 06/15/2026)

Adderall - Available

As promised joint dd with wolf:
Written by wolf on Reddit


First off, thanks to Hgils for the help on some of the research for this due diligence rabbit hole. Let's dive.

Ok, ELTP just had a stipulated agreement to drop legal dispute with Purdue, and I posted a few days ago on that. Nasrat Hakim, the CEO of Elite Pharma (ELTP), did a great job navigating that, just like he masterfully navigated ELTP out of any liability during the Opioid lawsuits going around over the last 10 years. He's notoriously conservative and strategic when it comes to litigation. So, WHY the sudden filing when Eliquis still has a patent and this will most likely lead to a lawsuit with them? Glad you asked.

We know that Nasrat is cautious in his approach to litigation. He's an attorney first, so this isn't a surprise. What IS a surpise, is this move on the ANDA filing. First, let's establish part of the ANDA (Abbreviated Novel Drug Application) process. When a company files an ANDA, and another company has an existing patent, the filing company will choose a path; a paragraph III filing or a paragraph IV filing. Paragraph III states they know there is a patent and they will "wait" it out. It's safer and doesn't include an exclusivity of 6 months to sell before any other generic companies can start selling. Paragraph IV carries more risk, but it has the 6 month exclusive upside. The chance that Elite is prepping for litigation here is high and it's not easy to win a paragraph IV. I believe one of the best ways to win P IV is to show that the company has a novel delivery of the drug that doesn't infringe on the existing drug patent.

How about a case where someone won a paragraph IV filing. Actavis filed an ANDA while Endo had a patented drug. Actavis was able to deftly demonstrate that their manufacturing process did not infringe on one of the Endo patents and they were able to secure a rare P IV win which allowed them early access to selling a new drug for the company and shareholders. Now, why am I bringing up a 13 year old case from Actavis? Guess who was a younger sharp VP at the company and helped them navigate this success? Our very own Nasrat Hakim. After that huge win, he used it to launch his move to CEO with ELTP and has earned a great amount of respect in the pharma community because of his track record. This is why I say ELTP is uniquely qualified for this ANDA filing, the timing, and the path to success. He's been there. He's done that.

If you're going to the Super Bowl, are you going to bet on Jim Kelly who got their 4 years in a row and couldn't get it done, or Tom Brady who won more than any other QB? We've got our quarterback and it's game time. It's not 4th and long anymore. It's 1st and goal.

Edit: Endo approval for actavis 2013

Nasrat joins elite 2013.

There is absolutely a difference. One sees all the Elite cards, the other does not.  

Lifesucks555

We could have a pr about the Purdue trial tomorrow or Wednesday.

What we know is based on DD and AI

There is no difference between Mikah and dexcel.

Both private companies doing business with elite.

Both can continue after the buyout.

So you would rather an outside partner .A partner that would be liability.  Maybe even from another country.  Try selling a company with that baggage. No harm was done. Even the SEC and the BOD says its fine.We were lucky to have this option.Explain what you would have done. It was going to be sold. Other buyers were ready. Sun did ELTP a solid. Now is completely different.  This is happening and happening real soon.

Your Google sounds like Henry. Except that he is at 12 cents lol

Try refreshing your Google search.  

What the heck did it do today ? Google says down a penny Edward Jones says up 3 Pennie’s

Over 10 years you have been dedicated to trying to tell me how bad this company is.

And your comments dont make any sense. What is your pecuniary interest in the company to bash it for 10 years? You can never answer that question. Seems odd to do this for 10 years while the company has gone from no earnings, no revenue to ~150m in revenue. No real debt. Super low Low PE.

Billion dollar generics filling the pipeline. Yes this one today is only $850m or whatever. Oxygen coming now. $26b in the pipeline.

Just wanted to stop by. Truth is i wouldnt be retired if it wasnt for the manipulation for more then 10 years which allowed me to accumulate. Dont worry, im not thanking you. But why didnt you just buy enough back then, and you wouldnt have to do this every day? I mean, i told you 1000x then too. Anyway. Back to the regularly schedule games.

10, 11, and 42, please!

How are fundamentals calculable with privately held Mikah pharmaceutical llc, intertwined with Elite.
Seems way south of sketchy, especially with the CEO of Elite owning Mikah, and absolutely refuses to discuss this conflict of fiduciary responsibilities owed to shareholders.
For this reason that is why...still for sale, and no takers

✅️ ELTP Catalyst ✅️

X 1. Cash Flow Positive 6 years
X 2. Cash Purchase of their original cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Launch Adderall IR $421.7 Million market
X 4. Launch Adderall XR $865 Million market
X 5. Create in house marketing and distribution with Kirko Kirkov and Doug Plassche
X 6. DEA increases manufacturing quotas for Adderall & Vyvance
X 7. Generic OxyContin - FDA submission Aug 17, 2023
X 8. Generic OxyContin filed with FDA Sept 2023 $720 Million
X 9. FDA Approval of a leased second manufacturing space and storage vault for new Needle Mover ANDAs
__10. Obtain Full ownership of generic Adderall IR $ 421.7 Million
__11. Obtain Full ownership of generic Adderall XR $ 865 Million
X 12. Launch generic Methotrexate $63 Million
X 13. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 14. International Distribution - partnership Approved by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite and Dexcel Ltd.
X 15. Generic IR Adderall® Receives Marketing Approval from the Israeli Ministry of Health Oct 2024
X 16. Generate revenues over $30 million/quarter
X 17. Generate revenues over $40 million/quarter
__18. Generate revenues over $50 million/quarter
X 19. Launch approved generic Tylenol with Codeine $47 Million
X 20. Launch approved generic Norco - Hydrocodone acetaminophen $300 Million
X 21. Launch approved generic Percocet - Oxycodone acetaminophen $317 Million
X 22. Launch approved generic Dolophine - Methadone HCL tablets $30 Million
X 23. Dopamine Agonist Approval Requip XL $12 Million
X 24. R&D Agreement with Indian Research and Development Co.
X 25. Generic Vyvanse Approval and Launch $4.3 Billion Generic Dec 2024
X 26. Launch Adderall IR in Israel
X 27. $150+ million revenues a year run rate
✅️ 28.Elite & Purdue/Knoa settle Generic OxyContin infringement suit.
Stipulation & order regarding irrevocable covenant not to market and dissmissal due to upcoming ADF patent expiration Aug 2027
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
✅️ 29. Positive Pivotal BE Undisclosed ANDA JUNE 2025 🔥 $26 Billion 🔥 generic anticoagulant
✅️ 30. FDA Submission $26 Billion generic anticoagulant
✅️ 31. Positive pivotal BE for $840 Million undisclosed AntiConvulsant ANDA Jun 2026
__32. Obtain Positive BE Study for generic Concerta CNS Stimulant $1.16 Billion
__33. Generic Concerta- FDA submission $1.16 Billion
__34. Generic Concerta Launch $1.16 Billion
__35. Generic OxyContin FDA Approval $720 Million
__36. Launch Generic OxyContin $720 Million
__37. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone (Drug C in SequestOx reformulation
__38. Purchase needle mover ANDA(s) with $Billion + market
__39. Deep Pocket Partner for SequestOx Abuse Deterrent Oxycodone
__40. Undisclosed Mikah ANDA(s)
__41. $200 million in yearly revenue
__42. Exercise the Warrants
__43. DollarLand SP
__44. Up List to NASDAQ exchange
✅️✅️✅️ 45. Select M&A advisory firm for buyout
✅️ 46. Perform Confidential Business Valuation
✅️ 47. First Buyer Walk Throughs
__48. Buyout offer/s
__49. Buyer Identified
__50. Buyout Vote of Board of Directors
__51. Halt Trading
__52. Shareholder vote on offer
__53. Buyout Closing Completed —$$$$$$$$$$$
__54. 🔥Vegas BABY !!!!! 🔥
Bullish
ELTP

That’s an easy answer Alex, what is low float and significant non trading inside ownership. It allow small volumes to move the stock

.

$0.80 to $2.59 per share
Way undervalued right now and not even factoring in generic Eliquis, generic OxyContin, now an undisclosed anticonvulsant generic, potential Dexcel expansion of generic Adderall & Vyvanse in Israel, the Trump Pharma tariff on foreign drug companies, and how may other drugs are in the pipeline going through the BE studies.
Cheers to Elite Pharmaceuticals’ scientists that have successfully reverse engineered these off patten drugs and passing the BE studies test. 

https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-eltp/elite-pharmaceuticals/valuation


https://elite.irpass.com/profiles/investor/ResLibraryView.asp?ResLibraryID=167323&BzID=2258&g=939&Nav=0&LangID=1&s=0

Well said. In the end, fundamentals will win out. 

Please explain.

ELTP continues to trade at a valuation that appears disconnected from its financial performance.

What valuation metrics are you employing to conclude Elite valuation is disconntected

would typically command a substantially higher multiple

What multiples are you referring to?

ELTP continues to trade at a valuation that appears disconnected from its financial performance. Record revenue, record earnings, and expanding profitability would typically command a substantially higher multiple, yet the stock remains valued as though its earnings power is temporary or uncertain. Whether that disconnect stems from microcap illiquidity, market structure inefficiencies, aggressive market maker activity, or simple institutional neglect is open to debate, but the result is the same: price has lagged fundamentals.

The bullish case is surprisingly straightforward. Current valuation levels already imply significant skepticism regarding the sustainability of earnings. If the company merely maintains its existing trajectory, the gap between market value and intrinsic value becomes increasingly difficult to justify. The longer profitability persists, the harder it becomes for the market to ignore, regardless of short-term trading dynamics or price suppression theories.

Let me in @  .35

Who is we ??

TIA

But... The Mikah issue will always be a road block, no matter how attractive things may appear. This probably has already factored into " thanks, but we're not interested"

Being that we don't know what the "other side" is like, I'll take LIFE for $2000 Alex.

😸😆😸😄😸😃😸😅😸🤣😹😂😹

Sorry , It wont make that much difference at THE buyout .

That’s the risk you run playing chicken with your shares… 🤷‍♂️

Never know when Nasrat might ram a positive BE trial up that A. 😬😭

Every bit of good news, like today's, just makes us a better buy-out candidate at a higher price.

You might need a LOT of help ??

The natives are getting restless.

LMAO~!

Those shares are looking very good right now. Good thing you didn’t listen to the shorts on here. 

Off Patent is better than waiting until 2030 !!!!!!!!!!!!!!!

We need revenue growth NOW,

IB_🤴🏻

Our Merger & Acquisition partner is working on finding us a suitor. If an acceptable offer is presented today, we’ll be more than happy to consider it. But if not, we will wait another quarter or two to show realistic revenues and profits that include Lisdex and show the trending for the sales of Lisdex, which would take the guesswork out of how much is the company is really worth. OK. The timetable for Merger & Acquisition is flexible.

Looks like more Elite news that fizzles out in a matter of hours.

Please share your success day trading ELTP for these little bumps in price

3 CENTS TODAY $0.17 to go by Friday ??
Hope your right.

GLTY

6 more drug releases and 10 billion revenue to sniff .60

Got a long wait to go boys

It’s almost twenty cent Friday

Lets keep the rumor train going. Choo-chooo. New Narratives are being created and given to the bagholders for some false hope! Choo chooo the red flags are flying high. Choo choo the Pump and dump is on. Choo choo OTC scam city is where your at. But now, the kicker is a few blame it on the MM or manipulation. Get out of here with that nonsense. The trajectory is south. Volume is lower, the lies are changing. SUB 12

Still opportunity here for anyone on the fence!!! Next 60 days could be the finale for lil ole ELTP!!!
Vegas Baby!!!

im thinking this cc will be when nasrat makes the speech of his life.....then momentum will push to dollarland....and the sale of elite

Karma is on its way.You can feel the momentum building.Buckel up!

any company that has accomplished so much in the past 2 years as elite would have been flying but these miserable mms are keeping us in check for diabolical reasons

✅️ ELTP Catalyst ✅️

✅️ 1. Cash Flow Positive 6 years
✅️ 2. Cash Purchase of their original cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
✅️ 3. Launch Adderall IR $421.7 Million market
✅️ 4. Launch Adderall XR $865 Million market
✅️ 5. Create in house marketing and distribution with Kirko Kirkov and Doug Plassche
✅️ 6. DEA increases manufacturing quotas for Adderall & Vyvance
✅️ 7. Generic OxyContin - FDA submission Aug 17, 2023
✅️ 8. FDA Acceptance of Generic OxyContin Sept 2023 $720 Million
✅️ 9. FDA Approval of a leased second manufacturing space and storage vault for new Needle Mover ANDAs
__10. Obtain Full ownership of generic Adderall IR $ 421.7 Million
__11. Obtain Full ownership of generic Adderall XR $ 865 Million
✅️ 12. Launch generic Methotrexate $63 Million
✅️ 13. Become the ONLY company showing rapid growth on the OTC while being profitable
✅️ 14. Put Opioids back on the Table- due to reduced risk of opioid litigation
✅️ 15. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
✅️ 16. International Distribution - partnership Approved by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
✅️ 17. Generic IR Adderall® Receives Marketing Approval from the Israeli Ministry of Health Oct 2024
✅️ 18. Generate revenues over $30 million/quarter
✅️ 19. Generate revenues over $40 million/quarter
__ 20. Generate revenues over $50 million/quarter
✅️ 21. Launch approved generic Tylenol with Codeine $47 Million
✅️ 22. Launch approved generic Norco - Hydrocodone acetaminophen $300 Million
✅️ 23. Launch approved generic Percocet - Oxycodone acetaminophen $317 Million
✅️ 24. Launch approved generic Dolophine - Methadone HCL tablets $30 Million
✅️ 25. Dopamine Agonist Approval Requip XL $12 Million
✅️ 26. R&D Agreement with Indian Research and Development Co.
__ 27. Obtain Positive BE Study for generic Concerta CNS Stimulant $1.16 Billion
✅️ 28. Generic Vyvanse Approval and Launch $4.3 Billion Generic Dec 2024
__29. Generic Concerta- FDA submission $1.16 Billion
✅️ 30. Launch Adderall IR in Israel
✅️ 31. $150+ million revenues a year run rate
✅️ 32. Accord Pharma prevail over Purdue in Generic OxyContin infringement suit Oct 06, 2025
✅️ 33. Elite & Purdue/Knoa settle Generic OxyContin infringement suit.
Stipulation & order regarding irrevocable covenant not to market and dissmissal due to upcoming ADF patent expiration Aug 2027
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
__34. Generic OxyContin FDA Approval $720 Million
__35. Launch Generic OxyContin $720 Million
__36. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone (Drug C in SequestOx reformulation trial )
__37. Deep Pocket Partner for SequestOx Abuse Deterrent Oxycodone
__38. $200 million in yearly revenue
__39. Undisclosed Mikah ANDA(s)
✅️ 40. DEA increases manufacturing quotas for Adderall & Vyvance for a second time - Oct 2025
✅️ 41. Positive Pivotal BE Undisclosed ANDA JUNE 2025 🔥 $26 Billion
et 🔥 generic anticoagulant
✅️ 42. DEA increases manufacturing quotas for Adderall & Vyvance AGAIN - Jan 2026
__43. Purchase needle mover ANDA(s) with $Billion + market
✅️ 44. Complete stability testing for $26 Billion anticoagulant
✅️ 45. FDA Submission $26 Billion generic anticoagulant
✅️ 46. Positive pivital BE for $840 Million undisclosed AntiConvulsant ANDA Jun 2026
__47. Generic Concerta Launch $1.16 Billion
__48. Exercise The Warrants
__49. DollarLand SP
__50. Up List to NASDAQ exchange
✅️ 51. Receive additional Analyst coverage from Zack’s Investment
✅️✅️✅️ 52. Select M&A advisory firm for buyout
✅️ 53. Perform Confidential Business Valuation
✅️ 54. First Buyer Walk Throughs
__55. Buyout offer/s
__56. Buyer Identified
__57. Buyout Vote of Board of Directors
__58. Halt Trading
__59. Shareholder vote on offer
__60. Buyout Closing Completed —$$$$$$$$$$$
__61. 🔥Vegas BABY !!!!! 🔥
Bullish
ELTP

I should have added “sustained” rip north! Still not selling my shares no matter the manipulation! ELTP$$$$$$$